---
layout: default
title: Antimony Trisulfide Berberis Vulgaris Root Bark Br
parent: 僅模型預測 (L5)
nav_order: 327
evidence_level: L5
indication_count: 0
---

# Antimony Trisulfide Berberis Vulgaris Root Bark Br
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Homeopathic Multi-Ingredient Formula (23 Components): No TxGNN Repurposing Prediction Available

## One-Sentence Summary

This product is a complex homeopathic combination formula containing 23 botanical, mineral, and biological ingredients — including Valerian, Passiflora incarnata, Digitalis, Datura stramonium, and Nux vomica — with no conventional pharmacological indication on record.
The TxGNN model was **unable to generate a repurposing prediction** for this entry, as the product lacks a DrugBank identifier, conventional mechanism of action data, and any registered indication that could serve as a graph node in the knowledge graph.
With **0 clinical trials** and **0 publications** linked to this specific formulation, the current evidence base is insufficient to support a repurposing analysis.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no registered indication found |
| Predicted New Indication | None — TxGNN did not return a prediction |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; in this case, no prediction returned) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

This product is a **homeopathic multi-ingredient formula** composed of 23 substances. Several are well-known classical homeopathic remedies (*Pulsatilla vulgaris*, *Sepia officinalis*, *Graphite*, *Lycopodium clavatum*); others are herbal agents with documented pharmacological activity at conventional doses (*Valerian*, *Passiflora incarnata*, *Scutellaria lateriflora*, *Hops*); and a subset are highly toxic plants used exclusively in extreme homeopathic dilution (*Datura stramonium*, *Strychnos nux-vomica*, *Digitalis*).

The TxGNN knowledge graph operates at the level of single chemical entities mapped to DrugBank nodes. This product has **no DrugBank ID**, no conventional approved indication, and no mechanism of action on record — meaning it cannot be anchored to the drug–disease graph. As a result, the prediction pipeline returned no candidates.

Because homeopathic combination products are not represented in the biomedical knowledge graph used by TxGNN, the absence of a prediction is **expected and not a data error**. Any repurposing claim for this formulation would need to be built from first principles, starting with individual active ingredient identification and dose characterisation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this specific multi-ingredient formulation.

---

## Literature Evidence

Currently no related literature available for this specific multi-ingredient formulation.

---

## Taiwan Market Information

This product has no licenses registered with the Taiwan FDA (TFDA). It is currently not marketed in Taiwan.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers**: Several ingredients in this formula carry significant intrinsic toxicity at non-homeopathic doses — notably *Digitalis* (cardiac glycosides), *Datura stramonium* (anticholinergic alkaloids), *Strychnos nux-vomica* (strychnine), and *Toxicodendron pubescens* (urushiol). If this product is ever evaluated at non-homeopathic concentrations, dedicated safety profiling for each ingredient will be mandatory. *Silver nitrate* also warrants caution due to potential argyria and tissue toxicity.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This submission cannot be evaluated by the standard TxGNN drug repurposing pipeline because the product is a homeopathic combination formula without a DrugBank anchor, a conventional mechanism of action, or any registered indication. The absence of a TxGNN prediction is structurally expected, not a pipeline failure.

**To proceed, the following is needed:**

- **Product identity clarification**: Confirm whether this is a registered homeopathic product (with a manufacturer and intended indication) or an investigational mixture — the 23-component string does not correspond to any known single branded product.
- **Ingredient-level decomposition**: If repurposing is desired, each pharmacologically active ingredient (e.g., Valerian, Passiflora, Scutellaria) should be analysed individually as a separate TxGNN query.
- **DrugBank ID assignment**: At minimum, the primary active botanical(s) must be mapped to a DrugBank node before the TxGNN pipeline can be applied.
- **Dose and concentration data**: Homeopathic dilution levels (e.g., 6X, 30C) must be specified to determine whether any ingredient reaches a pharmacologically relevant concentration.
- **Regulatory intent**: Clarify whether the goal is to evaluate this product as a whole or to use it as a source of candidate actives for repurposing — these require fundamentally different analytical approaches.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

